Evidence map›Paper›PMID 42798850›Full record

ArticleJCEM case reports2026

Antineoplastic effect of block-and-replace strategy for managing hypercortisolism caused by adrenal cortical carcinoma.

Davide Lorenzo Bettini, Sara Rodella, Marta Laganà, Antonella Turla, Alfredo Berruti, Deborah Cosentini

Abstract readCase Reports
In one paragraph

Article in JCEM case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Davide Lorenzo BettiniMedical Oncology, University of Brescia, ASST Spedali Civili Comprehensive Cancer Center, Brescia 25123, Italy.ORCID https://orcid.org/0009-0005-2356-6511
Sara RodellaMedical Oncology, University of Brescia, ASST Spedali Civili Comprehensive Cancer Center, Brescia 25123, Italy.ORCID https://orcid.org/0009-0004-3248-6655
Marta LaganàMedical Oncology, University of Brescia, ASST Spedali Civili Comprehensive Cancer Center, Brescia 25123, Italy.ORCID https://orcid.org/0000-0001-8457-122X
Antonella TurlaMedical Oncology, University of Brescia, ASST Spedali Civili Comprehensive Cancer Center, Brescia 25123, Italy.ORCID https://orcid.org/0000-0002-8018-588X
Alfredo BerrutiMedical Oncology, University of Brescia, ASST Spedali Civili Comprehensive Cancer Center, Brescia 25123, Italy.ORCID https://orcid.org/0000-0002-3956-0043
Deborah CosentiniMedical Oncology, University of Brescia, ASST Spedali Civili Comprehensive Cancer Center, Brescia 25123, Italy.ORCID https://orcid.org/0000-0001-8962-5020

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adrenocortical carcinoma (ACC) is a rare and aggressive malignancy frequently associated with cortisol hypersecretion, which confers substantial morbidity and a worse prognosis. In metastatic ACC, rapid control of Cushing syndrome is essential to allow systemic therapy. Although the block-and-replace strategy using steroidogenesis inhibitors is well established for cortisol control, its potential antineoplastic effects have not been previously reported. We describe 2 patients with metastatic ACC and severe Cushing syndrome treated with block-and-replace using osilodrostat or metyrapone. In both, cortisol normalized rapidly and safely, with marked clinical improvement. Unexpectedly, both experienced significant radiological tumor responses before exposure to effective cytotoxic chemotherapy and before therapeutic mitotane plasma concentrations were achieved. These cases suggest that steroidogenesis inhibition within a block-and-replace strategy may exert a direct or indirect antineoplastic effect in ACC. Although causality cannot be established, the temporal association between cortisol blockade and tumor response is compelling and warrants further prospective and translational investigation.

Indexed as

adrenocortical carcinomaCushing syndromemetyraponeosilodrostat

Identifiers

PMID42798850
PMCPMC13613213

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.